Amrutanjan Health Care Limited (AMRUTANJAN.NS)
INR 669.5
(5.93%)
INR 669.5
(5.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 681.59 Million INR | -12.09% |
| 2022 | 590.79 Million INR | -37.97% |
| 2021 | 946.98 Million INR | 10.02% |
| 2020 | 861.66 Million INR | 127.41% |
| 2019 | 391.52 Million INR | -0.65% |
| 2018 | 385.29 Million INR | 11.82% |
| 2017 | 361.72 Million INR | 2.06% |
| 2016 | 373.98 Million INR | -6.44% |
| 2015 | 357.95 Million INR | 26.89% |
| 2014 | 280.62 Million INR | 19.13% |
| 2013 | 236.78 Million INR | 8.46% |
| 2012 | 187.95 Million INR | -4.9% |
| 2011 | 229.74 Million INR | 28.19% |
| 2010 | 179.15 Million INR | -1.82% |
| 2009 | 201.19 Million INR | -7.03% |
| 2008 | 192.73 Million INR | 69.5% |
| 2007 | 112.89 Million INR | -29.41% |
| 2006 | 161.99 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 35.48 Million INR | -50.72% |
| 2023 Q4 | 162.36 Million INR | -35.92% |
| 2023 Q1 | 108.45 Million INR | -39.06% |
| 2023 FY | - INR | -12.09% |
| 2023 Q2 | 107.89 Million INR | -0.52% |
| 2023 Q3 | 253.37 Million INR | 134.83% |
| 2022 FY | - INR | -37.97% |
| 2022 Q1 | 63.41 Million INR | -70.52% |
| 2022 Q2 | 189.6 Million INR | 198.98% |
| 2022 Q3 | 158.33 Million INR | -16.49% |
| 2022 Q4 | 177.98 Million INR | 12.41% |
| 2021 Q2 | 272.29 Million INR | 57.48% |
| 2021 FY | - INR | 10.02% |
| 2021 Q3 | 288.22 Million INR | 5.85% |
| 2021 Q4 | 215.13 Million INR | -25.36% |
| 2021 Q1 | 172.91 Million INR | 14.75% |
| 2020 FY | - INR | 127.41% |
| 2020 Q1 | 96.54 Million INR | -17.71% |
| 2020 Q3 | 290.3 Million INR | -10.18% |
| 2020 Q2 | 323.21 Million INR | 234.79% |
| 2020 Q4 | 150.68 Million INR | -48.09% |
| 2019 Q3 | 138.67 Million INR | 3.18% |
| 2019 Q4 | 117.31 Million INR | -15.4% |
| 2019 Q1 | -42 Thousand INR | -100.02% |
| 2019 Q2 | 134.39 Million INR | 320090.48% |
| 2019 FY | - INR | -0.65% |
| 2018 Q2 | 102.97 Million INR | 887.23% |
| 2018 FY | - INR | 11.82% |
| 2018 Q4 | 207.63 Million INR | 148.0% |
| 2018 Q3 | 83.72 Million INR | -18.7% |
| 2018 Q1 | -13.08 Million INR | -111.53% |
| 2017 FY | - INR | 2.06% |
| 2017 Q1 | -8.98 Million INR | -111.35% |
| 2017 Q2 | 144.84 Million INR | 1711.94% |
| 2017 Q3 | 86.82 Million INR | -40.06% |
| 2017 Q4 | 113.49 Million INR | 30.71% |
| 2016 Q2 | 119.87 Million INR | 0.0% |
| 2016 FY | - INR | -6.44% |
| 2016 Q4 | 79.2 Million INR | -14.69% |
| 2016 Q3 | 92.83 Million INR | -22.56% |
| 2015 FY | - INR | 26.89% |
| 2014 FY | - INR | 19.13% |
| 2013 FY | - INR | 8.46% |
| 2012 Q4 | 83.42 Million INR | 32.36% |
| 2012 FY | - INR | -4.9% |
| 2012 Q2 | 57.67 Million INR | 355.2% |
| 2012 Q3 | 63.02 Million INR | 9.27% |
| 2012 Q1 | 12.67 Million INR | 0.0% |
| 2011 FY | - INR | 28.19% |
| 2010 FY | - INR | -1.82% |
| 2009 FY | - INR | -7.03% |
| 2008 FY | - INR | 69.5% |
| 2007 FY | - INR | -29.41% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Hester Biosciences Limited | 539.47 Million INR | -26.345% |
| RPG Life Sciences Limited | 1.28 Billion INR | 46.813% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 85.427% |
| Ipca Laboratories Limited | 13.29 Billion INR | 94.875% |
| Aarti Drugs Limited | 3.24 Billion INR | 79.019% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 82.565% |
| Albert David Limited | 1.04 Billion INR | 34.802% |
| Alembic Limited | 1.11 Billion INR | 38.944% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.183% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 92.912% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -494.849% |
| Bajaj HealthCare Limited | 406.23 Million INR | -67.782% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -5144.66% |
| Brooks Laboratories Limited | 41.72 Million INR | -1533.426% |
| Eris Lifesciences Limited | 6.98 Billion INR | 90.244% |
| FDC Limited | 3.38 Billion INR | 79.866% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 90.068% |
| Gufic Biosciences Limited | 1.48 Billion INR | 53.961% |
| Hikal Limited | 2.69 Billion INR | 74.683% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 90.067% |
| Ind-Swift Limited | 1.06 Billion INR | 36.004% |
| Innova Captab Limited | 1.66 Billion INR | 59.145% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 73.851% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -110.72% |
| Jubilant Pharmova Limited | 8 Billion INR | 91.486% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -137.139% |
| Laurus Labs Limited | 8 Billion INR | 91.486% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 49.26% |
| Lupin Limited | 36.96 Billion INR | 98.156% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -289.604% |
| Medico Remedies Limited | 129.09 Million INR | -427.984% |
| Morepen Laboratories Limited | 1.72 Billion INR | 60.509% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 55.613% |
| Orchid Pharma Limited | 1.41 Billion INR | 51.973% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 77.83% |
| Sigachi Industries Limited | 883.39 Million INR | 22.844% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 124.154% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.507% |
| Themis Medicare Limited | 562.6 Million INR | -21.15% |
| Unichem Laboratories Limited | 742.35 Million INR | 8.185% |
| Vaishali Pharma Limited | 31.71 Million INR | -2049.399% |
| Venus Remedies Limited | 711.8 Million INR | 4.243% |
| Wanbury Limited | 985.49 Million INR | 30.837% |
| Windlas Biotech Limited | 781.72 Million INR | 12.808% |
| ZIM Laboratories Limited | 462.09 Million INR | -47.501% |
| Sakar Healthcare Limited | 393.26 Million INR | -73.316% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.897% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.32% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 71.08% |
| Mankind Pharma Limited | 28.09 Billion INR | 97.574% |
| Sequent Scientific Limited | 549.8 Million INR | -23.972% |
| Neuland Laboratories Limited | 4.74 Billion INR | 85.645% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 92.698% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 93.991% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.788% |
| Wockhardt Limited | 1.08 Billion INR | 36.889% |
| Bal Pharma Limited | 345.59 Million INR | -97.226% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.228% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 53.916% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -198.718% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 88.978% |
| Shilpa Medicare Limited | 2.58 Billion INR | 73.663% |
| Valiant Laboratories Limited | 12.73 Million INR | -5250.467% |
| Ajanta Pharma Limited | 12.56 Billion INR | 94.576% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -1409.124% |
| Granules India Limited | 8.6 Billion INR | 92.078% |
| Medicamen Biotech Limited | 245.66 Million INR | -177.455% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -58.409% |
| Piramal Enterprises Limited | -3.86 Billion INR | 117.653% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.053% |
| NATCO Pharma Limited | 18.79 Billion INR | 96.374% |
| Suven Life Sciences Limited | -992.78 Million INR | 168.655% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 923.91% |
| Strides Pharma Science Limited | 3.76 Billion INR | 81.895% |
| Indoco Remedies Limited | 2.64 Billion INR | 74.251% |
| Alpa Laboratories Limited | 229.96 Million INR | -196.396% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1147.32% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 118.266% |